Assessing and reducing risk for colorectal cancer
Block23’s first genomic test is Colo-Prevent, a clinically validated screen test for colorectal cancer (CRC), a disease with the 2nd highest occurrence of cancer. Based on genomic tests conducted on over 42,000 colorectal cancer patients and linked to personal data and lifestyle habits, Colo-Prevent represents an accurate reading of risk and offers a guide for managing your health.
Take a personal data and lifestyle risk assessment
This tool calculates the potential risk of colorectal cancer over the next 5 years, 10 years, and the lifetime risk for people over 50 years of age. The questionnaire takes about 5 minutes to complete. Combined with the Block23 genomic test for measuring genetic risk factors, doctors and patients can better understand the personal risk of colorectal cancer.
Take a test to know your genomic risk
In addition to your personal and lifestyle risk, your genome may increase or lower your risk. A DNA Saliva Specimen Kit is sent to each individual for genomic analysis. The Colo-Prevent risk score is determined following analysis of the individual’s DNA by an algorithm programmed into encrypted software generating a patient report of relative lifetime risk of developing CRC.